Literature DB >> 30277015

Association of hypocalcemia with congenital heart disease in 22q11.2 deletion syndrome.

Arpana Rayannavar1, Lorraine E Levitt Katz1, Terrence Blaine Crowley2, Megan Lessig1, Katheryn Grand2, Elizabeth Goldmuntz3, Elaine H Zackai2, Donna M McDonald-McGinn2.   

Abstract

Hypocalcemia is one of the cardinal features of the chromosome 22q11.2 deletion syndrome (22q11.2DS), the most common cause of DiGeorge syndrome. Hypocalcemia and other features of 22q11.2DS including congenital heart disease (CHD) are primarily ascribed to problems with morphogenesis and function of the pharyngeal arch system derivatives including the parathyroid glands, the aortic arch, and the cardiac outflow tract. In light of the aforementioned embryology, we hypothesized that hypocalcemia would be identified more frequently in those patients with 22q11.2DS and CHD. We conducted a retrospective IRB approved chart review on 1,300 subjects with 22q11.2DS evaluated at the Children's Hospital of Philadelphia. χ2 test was used to evaluate the statistical significance of differences in hypocalcemia between the two groups. Eight hundred fifty-two patients had calcium levels available for review. Of these, 466 (54.69%) had a history of hypocalcemia and 550 (64.55%) had CHD. Of those with CHD, 343 (62.36%) had a history of hypocalcemia, and of those without CHD, only 123 (40.73%) had a history of hypocalcemia. Thus, the frequency of diagnosed hypocalcemia was greater in patients with 22q11.2DS and CHD as compared to those without CHD (p < .001). We also analyzed age of onset of hypocalcemia and found that 66.47% of CHD/hypocalcemia group had neonatal/infantile hypocalcemia versus 43.09% in the non-CHD/hypocalcemia group. In our large cohort of patients with 22q11.2DS, the prevalence of diagnosed hypocalcemia is elevated among patients with CHD, in whom it is more likely to be diagnosed during the neonatal/infancy period.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  congenital heart disease; hypocalcemia22q11.2 microdeletion

Mesh:

Year:  2018        PMID: 30277015      PMCID: PMC6467273          DOI: 10.1002/ajmg.a.40495

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  14 in total

1.  Endocrine manifestations of chromosome 22q11.2 microdeletion syndrome.

Authors:  Jin-Ho Choi; Young-Lim Shin; Gu-Hwan Kim; Eul-Ju Seo; Youngho Kim; In-Sook Park; Han-Wook Yoo
Journal:  Horm Res       Date:  2005-07-01

Review 2.  The clinical, immunological, and molecular spectrum of chromosome 22q11.2 deletion syndrome and DiGeorge syndrome.

Authors:  Kathleen E Sullivan
Journal:  Curr Opin Allergy Clin Immunol       Date:  2004-12

3.  Prevalence of recurrent pathogenic microdeletions and microduplications in over 9500 pregnancies.

Authors:  Francesca Romana Grati; Denise Molina Gomes; Jose Carlos Pinto B Ferreira; Celine Dupont; Viola Alesi; Laetitia Gouas; Nina Horelli-Kuitunen; Kwong Wai Choy; Sandra García-Herrero; Alberto Gonzalez de la Vega; Krzysztof Piotrowski; Rita Genesio; Gloria Queipo; Barbara Malvestiti; Bérénice Hervé; Brigitte Benzacken; Antonio Novelli; Philippe Vago; Kirsi Piippo; Tak Yeung Leung; Federico Maggi; Thibault Quibel; Anne Claude Tabet; Giuseppe Simoni; François Vialard
Journal:  Prenat Diagn       Date:  2015-06-24       Impact factor: 3.050

4.  Clinical manifestations and frequency of hypocalcemia in 22q11.2 deletion syndrome.

Authors:  Sachiko Fujii; Toshio Nakanishi
Journal:  Pediatr Int       Date:  2015-11-26       Impact factor: 1.524

5.  The Philadelphia story: the 22q11.2 deletion: report on 250 patients.

Authors:  D M McDonald-McGinn; R Kirschner; E Goldmuntz; K Sullivan; P Eicher; M Gerdes; E Moss; C Solot; P Wang; I Jacobs; S Handler; C Knightly; K Heher; M Wilson; J E Ming; K Grace; D Driscoll; P Pasquariello; P Randall; D Larossa; B S Emanuel; E H Zackai
Journal:  Genet Couns       Date:  1999

Review 6.  The 22q11 deletion syndromes.

Authors:  P J Scambler
Journal:  Hum Mol Genet       Date:  2000-10       Impact factor: 6.150

7.  A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population.

Authors:  Lorenzo D Botto; Kristin May; Paul M Fernhoff; Adolfo Correa; Karlene Coleman; Sonja A Rasmussen; Robert K Merritt; Leslie A O'Leary; Lee-Yang Wong; E Marsha Elixson; William T Mahle; Robert M Campbell
Journal:  Pediatrics       Date:  2003-07       Impact factor: 7.124

8.  22q11.2 Deletion syndrome is associated with perioperative outcome in tetralogy of Fallot.

Authors:  Laura Mercer-Rosa; Nelangi Pinto; Wei Yang; Ronn Tanel; Elizabeth Goldmuntz
Journal:  J Thorac Cardiovasc Surg       Date:  2013-01-11       Impact factor: 5.209

Review 9.  Endocrine aspects of the 22q11.2 deletion syndrome.

Authors:  S A Weinzimer
Journal:  Genet Med       Date:  2001 Jan-Feb       Impact factor: 8.822

10.  Parathyroid hormone reserve in 22q11.2 deletion syndrome.

Authors:  Chirag R Kapadia; Yuran E Kim; Donna M McDonald-McGinn; Elaine H Zackai; Lorraine E Levitt Katz
Journal:  Genet Med       Date:  2008-03       Impact factor: 8.822

View more
  1 in total

1.  Testing criteria for 22q11.2 deletion syndrome: preliminary results of a low cost strategy for public health.

Authors:  Ilária Cristina Sgardioli; Fabíola Paoli Monteiro; Paulo Fanti; Társis Paiva Vieira; Vera Lúcia Gil-da-Silva-Lopes
Journal:  Orphanet J Rare Dis       Date:  2019-06-03       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.